esorubicin has been researched along with Cardiac Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Green, M; Modeas, C; Muss, HB; Norton, L; Perry, MC; Propert, KJ; Ringenberg, QS; Schilsky, RL; Weiss, RB | 1 |
| Campbell, T; Henderson, IC; Korzun, AH; Muss, HB; Rice, MA; Van Echo, D; Vogelzang, NJ; Wood, W | 1 |
2 other study(ies) available for esorubicin and Cardiac Failure
| Article | Year |
|---|---|
Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Arrhythmias, Cardiac; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Evaluation; Female; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pancoast Syndrome | 1990 |
Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Drug Evaluation; Female; Heart; Heart Failure; Humans; Middle Aged; Nausea; Remission Induction | 1990 |